TY - JOUR
T1 - Relevance of Fluorinated Ligands to the Design of Metallodrugs for Their Potential Use in Cancer Treatment
AU - Páez-Franco, José C.
AU - Zermeño-Ortega, Miriam R.
AU - de la O-Contreras, Carmen Myriam
AU - Canseco-González, Daniel
AU - Parra-Unda, Jesus R.
AU - Avila-Sorrosa, Alcives
AU - Enríquez, Raúl G.
AU - Germán-Acacio, Juan M.
AU - Morales-Morales, David
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2
Y1 - 2022/2
N2 - Fluorination of pharmaceutical agents has afforded crucial modifications to their pharmacological profiles, leading to important advances in medicinal chemistry. On the other hand, metallodrugs are considered to be valuable candidates in the treatment of several diseases, albeit with the caveat that they may exhibit pharmacological disadvantages, such as poor water solubility, low bioavailability and short circulating time. To surmount these limitations, two approaches have been developed: one based on the design of novel metallodrug-delivering carriers and the other based on optimizing the structure of the ligands bound to the metal center. In this context, fluorination of the ligands may bring beneficial changes (physicochemical and biological) that can help to elude the aforementioned drawbacks. Thus, in this review, we discuss the use of fluorinated ligands in the design of metallodrugs that may exhibit potential anticancer activity.
AB - Fluorination of pharmaceutical agents has afforded crucial modifications to their pharmacological profiles, leading to important advances in medicinal chemistry. On the other hand, metallodrugs are considered to be valuable candidates in the treatment of several diseases, albeit with the caveat that they may exhibit pharmacological disadvantages, such as poor water solubility, low bioavailability and short circulating time. To surmount these limitations, two approaches have been developed: one based on the design of novel metallodrug-delivering carriers and the other based on optimizing the structure of the ligands bound to the metal center. In this context, fluorination of the ligands may bring beneficial changes (physicochemical and biological) that can help to elude the aforementioned drawbacks. Thus, in this review, we discuss the use of fluorinated ligands in the design of metallodrugs that may exhibit potential anticancer activity.
KW - Anticancer activity
KW - Cancer
KW - Coordination complexes
KW - Cytotoxicity
KW - Fluorinated ligands
KW - Metallodrugs
KW - Organometallics
UR - http://www.scopus.com/inward/record.url?scp=85124837319&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics14020402
DO - 10.3390/pharmaceutics14020402
M3 - Artículo de revisión
C2 - 35214133
AN - SCOPUS:85124837319
SN - 1999-4923
VL - 14
JO - Pharmaceutics
JF - Pharmaceutics
IS - 2
M1 - 402
ER -